Abstract
It has been hypothesized that Alzheimer disease (AD) is primarily a disorder of the synapse. However, assessment of the synaptic proteome in AD subjects has been limited to a small number of proteins and often included subjects with end-stage pathology. Protein from prefrontal cortex gray matter of 59 AD subjects with mild to moderate dementia and 12 normal elderly subjects was assayed using targeted mass spectrometry to quantify 191 synaptically expressed proteins. The profile of synaptic protein expression clustered AD subjects into two groups. One of these was characterized by reduced expression of glutamate receptor proteins, significantly increased synaptic protein network coexpression, and associated with Apolipoprotein E∗4 (APOE∗4) carrier status. The second group, by contrast, showed few differences from control subjects. A subset of AD subjects had altered prefrontal cortex synaptic proteostasis for glutamate receptors and their signaling partners. Efforts to therapeutically target glutamate receptors in AD may have outcomes dependent on APOE∗4 genotype.
Cite
CITATION STYLE
Sweet, R. A., MacDonald, M. L., Kirkwood, C. M., Ding, Y., Schempf, T., Jones-Laughner, J., … Yates, N. A. (2016). Apolipoprotein E∗4 (APOE∗4) genotype is associated with altered levels of glutamate signaling proteins and synaptic coexpression networks in the prefrontal cortex in mild to moderate Alzheimer disease. Molecular and Cellular Proteomics, 15(7), 2252–2262. https://doi.org/10.1074/mcp.M115.056580
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.